Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of the Double Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes Isolated or Not Compared to the Single Haploinsufficiency of RBM22 and Normal Karyotype Myelodysplastic Syndromes.

NCT04701229 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04701229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04701229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of the Double Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes Isolated or Not Compared to the Single Haploinsufficiency of RBM22 and Normal Karyotype Myelodysplastic Syndromes.
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2020
Completion date
September 30, 2023
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome with del(5q), myelodysplastic syndrome with isolated del(5q), myelodysplastic syndromes